Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
May 28th, 2019
11.2K views
Herein, we present a protocol for postconditioning with lactate-enriched blood, which is a novel approach for cardioprotection. This protocol comprises intermittent reperfusion and timely coronary injections of lactated Ringer's solution. This can be applied to ST-segment elevation myocardial infarction patients who undergo primary percutaneous coronary intervention.
Overview
This article presents a protocol for postconditioning with lactate-enriched blood, aimed at enhancing cardioprotection during myocardial infarction. The method involves intermittent reperfusion and coronary injections of lactated Ringer's solution, making it applicable for patients undergoing primary percutaneous coronary intervention.
Key Study Components
Area of Science
- Cardiovascular Medicine
- Interventional Cardiology
- Myocardial Infarction Treatment
Background
- Postconditioning is a technique used to protect the heart muscle during reperfusion.
- Lactate-enriched blood may enhance recovery from ischemic conditions.
- Standard methods may not be accessible or effective for all patients.
- Visual demonstrations can aid in the implementation of complex procedures.
Purpose of Study
- To develop a safe and effective protocol for postconditioning using lactate-enriched blood.
- To improve outcomes for patients with ST-segment elevation myocardial infarction.
- To demonstrate the procedure in a clear and reproducible manner.
Methods Used
- Coronary angiography to identify occluded lesions.
- Use of a balloon catheter for intermittent reperfusion.
- Injection of lactated Ringer's solution into the coronary artery.
- Monitoring of coronary flow and electrocardiography data.
Main Results
- Successful restoration of coronary flow in patients treated with the protocol.
- Improvement in aortic systolic pressure post-procedure.
- Achievement of thrombolysis in myocardial infarction flow grade III.
- Complete ST resolution observed in electrocardiography post-treatment.
Conclusions
- The protocol is safe and can be performed in standard catheterization laboratories.
- It effectively enhances myocardial recovery during reperfusion.
- Visual aids and demonstrations are crucial for successful implementation.
Frequently Asked Questions
What is postconditioning with lactate-enriched blood?
It is a novel cardioprotective method involving intermittent reperfusion and lactated Ringer's solution injections.
How does this method improve patient outcomes?
It enhances recovery from ischemic conditions during myocardial infarction treatment.
Is special equipment required for this procedure?
No, the method can be performed with standard catheterization lab equipment.
What are the key steps in the protocol?
Key steps include balloon catheter placement, contrast medium injection, and lactated Ringer's solution administration.
What results were observed in the study?
The study reported successful coronary flow restoration and improved patient hemodynamics.
Can this method be applied globally?
Yes, it is designed to be safe and accessible in catheterization labs worldwide.
Executive Industry Relevance
Postconditioning with lactate-enriched blood (PCLeB) addresses a critical unmet need in ST-segment elevation myocardial infarction (STEMI) treatment by targeting reperfusion injury, a major limitation of current percutaneous coronary intervention (PCI) strategies. The method enhances cardioprotection through controlled reperfusion dynamics and intracellular acidosis modulation, offering a mechanistically grounded approach to improve myocardial salvage. Its reliance on standard catheterization lab equipment supports broad translational potential for early-phase therapeutic development and mechanistic de-risking in cardiovascular drug discovery pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of reperfusion injury mechanisms and lactate-mediated cardioprotective pathways in ischemic heart disease models.
- Operational Value: Provides a reproducible, equipment-free protocol for functional validation of cytoprotective targets in ex vivo and preclinical ischemia-reperfusion systems.
- Predictive Value: Supports target confidence by linking lactate handling to functional outcomes such as ST resolution and myocardial viability preservation.
Screening & Assay Development
- Assay Readiness: Generates quantifiable hemodynamic and electrocardiographic endpoints (e.g., aortic systolic pressure, thrombolysis in myocardial infarction flow grade, ST resolution) suitable for compound screening in ischemia-reperfusion models.
- Standardization: Defines precise temporal parameters for intermittent reperfusion cycles and lactate delivery, enhancing assay reproducibility across laboratories.
- Scalability: Uses widely available angiographic and infusion tools, facilitating adaptation to high-content screening platforms for cardioprotective agent evaluation.
Translational & Preclinical Research
- Disease Relevance: Models human STEMI pathophysiology through coronary balloon occlusion and reperfusion in large animal or ex vivo heart systems.
- Translational Continuity: Bridges mechanistic discovery to preclinical validation by preserving myocardial viability and enabling functional recovery assessment post-intervention.
- Risk-Adjusted Advancement: Informs go/no-go decisions by quantifying reperfusion efficacy through thrombolysis grade restoration and hemodynamic stabilization.
Pipeline & Workflow Integration
PCLeB fits within the cardiovascular discovery continuum from target validation through preclinical efficacy testing, providing a standardized method to assess cardioprotective interventions in ischemia-reperfusion injury models.
- Discovery Biology: Supports hypothesis testing of lactate signaling pathways and acidosis modulation in cardiomyocyte survival mechanisms.
- Screening: Enables standardized assessment of compound effects on coronary flow restoration and reperfusion injury mitigation.
- Analytics: Delivers quantitative hemodynamic and electrocardiographic readouts for comparative analysis across treatment conditions.
- Translational Research: Aligns with preclinical continuity by demonstrating preserved myocardial viability and functional recovery.
- Enterprise Reuse: Represents a reusable platform for evaluating multiple cardioprotective candidates using identical procedural parameters.
Operational & Enterprise Impact
- Scientific Value: Mechanistic de-risking of reperfusion injury pathways through lactate-mediated intracellular acidosis control.
- Operational Value: High reproducibility and standardization using existing catheterization lab infrastructure.
- Strategic Value: Improved prediction of clinical translatability by reducing biological variability in ischemia-reperfusion models.
- Portfolio Impact: Enables data-driven prioritization of cardioprotective leads based on functional recovery and myocardial salvage metrics.
Implementation Considerations
- Requires interventional cardiology expertise for coronary angiography and balloon manipulation.
- Dependent on standard angiographic equipment, lactated Ringer's solution, and contrast medium.
- Necessitates coordination between primary and secondary operators for timed balloon inflation and solution injection.
- Adaptation to ex vivo or preclinical models may require adjustments in cycle timing and solution volumes.
- Limited to investigational use; clinical translation requires formal safety and efficacy validation.
Biopharma FAQs
Why is lactate enrichment used in postconditioning for cardioprotection?
Lactate enrichment aims to delay recovery from intracellular acidosis during reperfusion, thereby enhancing the cardioprotective effects of intermittent ischemia. This controlled reperfusion strategy minimizes lactate washout and supports sustained tissue oxygenation in the ischemic myocardium.
How does intermittent reperfusion with balloon inflation isolate the independent variable in PCLeB?
The independent variable—duration of reperfusion and lactate exposure—is isolated by systematically increasing reperfusion duration from 10 to 60 seconds across cycles while maintaining fixed 60-second ischemic intervals. This design enables testing of reperfusion timing effects on myocardial recovery.
What quantitative dependent variable measurements enable assessment of PCLeB efficacy?
Efficacy is assessed via thrombolysis in myocardial infarction (TIMI) flow grade restoration, aortic systolic pressure changes, electrocardiographic ST-segment resolution, and myocardial viability preservation measured by thallium scintigraphy.
Why are seven reperfusion-ischemia cycles required for cross-functional collaboration in PCLeB implementation?
Seven cycles ensure sufficient lactate trapping and acidosis modulation to achieve consistent reperfusion effects, enabling reliable comparison across operators and laboratories. This repetition supports standardization essential for multi-site preclinical or clinical studies.
What statistical analysis capabilities are required before implementing PCLeB in a discovery setting?
Implementation requires capability to analyze hemodynamic trends, electrocardiographic changes, and perfusion grades across repeated cycles. Comparative statistical evaluation of pre- and post-intervention metrics is necessary to determine significant improvements in coronary flow and myocardial salvage.
